Cargando…

Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7)

Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of patients with high-risk diseases (stage IV, and incompletely...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colomban, Olivier, Tod, Michel, Peron, Julien, Perren, Timothy J, Leary, Alexandra, Cook, Adrian D, Sajous, Christophe, Freyer, Gilles, You, Benoit
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306189/ https://www.ncbi.nlm.nih.gov/pubmed/32596636 http://dx.doi.org/10.1093/jncics/pkaa026

Ejemplares similares

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer
por: González Martín, Antonio, et al.
Publicado: (2019)

Front-Line Maintenance Therapy in Advanced Ovarian Cancer—Current Advances and Perspectives
por: Reverdy, Thibaut, et al.
Publicado: (2020)

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
por: Oza, Amit M, et al.
Publicado: (2015)

Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives
por: Varnier, Romain, et al.
Publicado: (2021)

COVID-19 Presentation and Outcomes among Cancer Patients: A Matched Case-Control Study
por: Péron, Julien, et al.
Publicado: (2021)

Her2 Expression in Circulating Tumor Cells Is Associated with Poor Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Maillet, Denis, et al.
Publicado: (2021)

The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review
por: Lauby, Ambroise, et al.
Publicado: (2021)

Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era
por: You, Benoit, et al.
Publicado: (2022)

Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial
por: Blagden, Sarah P, et al.
Publicado: (2020)

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2022)

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
por: Stark, Dan, et al.
Publicado: (2013)

Testing of Candidate Icons to Identify Acetaminophen-Containing Medicines
por: Shiffman, Saul, et al.
Publicado: (2016)

Methods and Designs of Modern Breast Cancer Confirmatory Trials
por: Péron, Julien, et al.
Publicado: (2021)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

Trajectories of disease courses in the inception cohort of newly diagnosed patients with JIA (ICON-JIA): the potential of serum biomarkers at baseline
por: Ganeva, Margarita, et al.
Publicado: (2021)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

Prediction of tumour response induced by chemotherapy using modelling of CA-125 kinetics in recurrent ovarian cancer patients
por: Wilbaux, M, et al.
Publicado: (2014)

Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
por: Suh, Young Ju, et al.
Publicado: (2022)

Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
por: Hettle, Robert, et al.
Publicado: (2021)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2015)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

Icones Roumaines
por: Nicolescu, Corina
Publicado: (1971)

Phonological iconicity
por: Schmidtke, David S., et al.
Publicado: (2014)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005–2022
por: Oster, Christoph, et al.
Publicado: (2023)

The equations: icons of knowledge
por: Bais, Sander
Publicado: (2005)

The Birth of an Anatomical Icon
Publicado: (1999)

ICON: chronic rhinosinusitis
por: Bachert, Claus, et al.
Publicado: (2014)

ICON: Eosinophil Disorders
por: Valent, Peter, et al.
Publicado: (2012)

Iconic gesturing in bonobos
por: Genty, Emilie, et al.
Publicado: (2015)

ICON 2020 Supplement
por: Saeed, Saima, et al.
Publicado: (2020)

ICON 2022 Supplement
por: Amanullah, Farhana, et al.
Publicado: (2022)

Effects of Users’ Familiarity With the Objects Depicted in Icons on the Cognitive Performance of Icon Identification
por: Shen, Zhangfan, et al.
Publicado: (2018)

Icons of architecture : the 20th century /
Publicado: (1998)

Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study
por: Oza, Amit M., et al.
Publicado: (2017)

Adherence to oral anticancer chemotherapy: What influences patients’ over or non-adherence? Analysis of the OCTO study through quantitative–qualitative methods
por: Bourmaud, Aurélie, et al.
Publicado: (2015)

CORRIGENDUM to “Effects of Users’ Familiarity With the Objects Depicted in Icons on the Cognitive Performance of Icon Identification”
Publicado: (2020)

Nudge and bias in subjective ratings? The role of icon sets in determining ratings of icon characteristics
por: McDougall, Siné, et al.
Publicado: (2022)

Modified Intraperitoneal Chemotherapy Without Bevacizumab as a First-Line Therapy for Newly Diagnosed Advanced Epithelial Ovarian Cancer-Two Centers Experiences
por: Shen, Yuanming, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nlm0j7nccfv9e5bq8k182lvkck